anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:The titled tablet having raised biological effectiveness as an antiphlogistic, obtained by using lactose granules granulated with a hydrophilic substance as a carrier, dispersing uniformly flurbiprofen on the surface of the carrier. CONSTITUTION:lactose is granulated with a hydrophilic substance(e.g., sucrose, hydroxypropyl cellulose) to give lactose granules, which are used as a carrier. Flurbiprofen[chemical name: 2-(2-fluoro-4-biphenylyl)propionic acid] is uniformly dispersed on the surface of the carrier of lactose granules, and, if necessary, an excipien, disintegrator, and lubricant are added to it, to give a flurbiprofen tablet. Flurbiprofen is slightly soluble, and pulverized to raise the biological effectiveness of the slightly-soluble drug. Flurbiprofen increases the adhesion force between granules by pulverization, and it has a fault such as partial pressure of contents. The use of the carrier improves the compressibility and flow properties of flurbiprofen, and a tablet with uniform contents can be obtained.
The invention provides tissue regeneration promoting styptic powder used for curing traumata, injuries, scald, infection or skin and external diseases of human beings caused in daily life at home, work, travel, soldiery and war, and because of the autoimmunity of human bodies and so on. The tissue regeneration promoting styptic powder is prepared from Chinese compound traditional herb medicaments which are porphyrized by adopting the modern technology. The tissue regeneration promoting styptic powder is characterized in that the formula ingredients of the tissue regeneration promoting stypic powder include Malan Straw, hyacinth bletilla, madeira vine, agrimony, madder and so on. The tissue regeneration promoting styptic powder has the functions of hemostasia, antiinflammation, eliminating erosion and promoting regeneration of tissues, improving the content of secretion and serum lysozyme, improving the resistance of the surfaces of wound, and accelerating the healing of surfaces of wound. The tissue regeneration promoting styptic powder can solve new and old injuries, acute and chronic ulcer syndromes effectively and safely. In addition, little time is needed for the powder to stanch bleeding, and wound can be healed quickly. The powder is effective for cure comprehensively. In the areas short of medical and sanitary conditions, or in particular cases, the tissue regeneration promoting styptic powder can ensure the health of the sick and wounded , and relieve the pain of the sufferers,and is in particular significant for war on battleground. The tissue regeneration promoting styptic powder can bring high economic benefits and social benefits.
The present invention provides methods for determining a personal improvement potential of physiological characteristics of human faces or other body parts. This may involve determining an objective score of at least one physiological characteristic, in particular an attractiveness and/or youthfulness score, of the face of a human user. More specifically, the invention provides a computer-implemented body part analysis method. The method may comprise an image acquisition step, comprising obtaining one or more digital images of at least one body part of a user, in particular the user's face, captured by an image capturing device. The method may further comprise an image processing step, comprising detecting one or more biometric parameters of the at least one body part in the captured one or more digital images. Still further, the method may comprise an evaluation step, comprising determining a score for each of one or more physiological characteristics of the at least one body part based on the detected one or more biometric parameters.
The present invention relates to an intestinal coated granule and a preparation method thereof. The intestinal coated granule is prepared from the medicine of 12g of senna leaf, 6g of common aucklandia root and 6g of green tangerine peel. The common aucklandia root and the green tangerine peel are distilled by vapor for extracting benzine containing beta-cyclodextrin, and the reflux extraction of medicine dregs and the senna leaf is carried out by 50% of alcohol with the pH value of 4.0 in a micro boiling mode. An extracting solution is processed through filtration, concentration and spray drying for obtaining dry powder, and then, microcrystalline cellulose and an inclusion compound are mixed with the dry powder. 90% of alcohol is used for moistening the dry powder, the microcrystalline cellulose and the inclusion compound which are quickly stirred for being prepared into granules. The granules are dried by hot air at a temperature of 50 DEG C in a liquid mode, and then, the granules are coated by an intestinal solubility coat material for being prepared into an intestinal tract controlled release preparation with the granule diameter of 500 to 1500 mum. The intestinal tract controlled release preparation can overcome the destruction of stomach strong acids and inner environment and outer environment, such as light, heat, etc., to the sennoside of the intestinal tract controlled release preparation, enhance medicine stability, guarantee the complete release of active components in the intestinal tracts, and sufficiently exert medicine curative effects. The intestinal coated granule is mainly used for the cleaning preparation of the intestinal tracts before abdomen video examination, surgery operations and gynecology operations, and can be used for the cure of various constipation, intestinal functional restoration after operations, etc. The present invention has high creativity and applicability, and is worth widely popularizing.
Design: Retrospective study based on clinico-genetic data. Total research duration: 22 months Plan of the study : More than 150 patients referred for ARCA suspicion have been analyzed by NGS (Montpellier platform) since September 2013. The clinical data of these patients will be entered at the computer level into the algorithm to obtain the prediction of the gene involved (under the form of a probability for each of the genes known to ARCA). The investigators will compare this result with that obtained by standard NGS analysis. For patients without molecular diagnosis defined after standard NGS analysis, the investigators will take the 5 most probable genes selected on the basis of the algorithm in order to carry out an in-depth analysis of the variants found and a bioinformatic analysis by semi-automatic detection of CNVs. Main Evaluation Criterion: Concordance of the algorithm with standard NGS analysis for the genetic diagnosis of ARCA. Secondary evaluation criterion:% of patients for whom the prediction based on the algorithm suggested the correct diagnosis (subsequently confirmed after revision in the detail of the genetic data) while the standard genetic analysis was not not informative. Statistical Analysis: The investigators will perform a concordance analysis (Cohen's k) to validate the algorithm in clinical practice. For a given patient, there will be concordance if: i) one of the first 5 genes predicted with the highest probability by the algorithm is compatible with the mutation found after standard NGS or ii) if no gene is predicted by the algorithm (score \<20) and no mutation found by NGS analysis.
Herpes Zoster (HZ) is a common complication of kidney transplant because of the immune suppressive drugs necessary to prepare the recipient for the transplanted organ and to protect it from rejection. The use of the live vaccine, Zostavax, in transplant recipients is contraindicated due to their impaired immune status. This study is being done to determine vaccine responses to the FDA approved shingles vaccine, Shingrix, in patients with chronic renal failure eligible for kidney transplant. Persistence of immune responses after kidney transplantation, and immunologic advantage of a third dose of Shingrix to renal transplant recipients will be assessed. Additionally, safety, tolerability, and occurrence of HZ will be evaluated. 60 participants will be enrolled from the renal transplant services at University of Colorado Anschutz Medical Campus.
PURPOSE:To obtain an ophthalmic composition, containing 13,14-dihydro-15-keto- prostaglandins and a beta-adrenergic blocker as active ingredients, excellent in intraocular hypotensive action and reduced in side effects. CONSTITUTION:An ophthalmic composition is obtained by including (a) 13,14- dihydro-15-keto-prostaglandins or their salts and esters thereof and (b) a beta- adrenergic blocker as active ingredients. The ingredients are blended in the following amounts. 0.005-2wt.% ingredient (a) and 0.005-20wt.% ingredient (b) at a blending ratio of the ingredients (a) to (b) within the range of (1:0.5)-(1:200). The composition is prepared into the form of a solution, an emulsion, a suspension or a gel, an ophthalmic ointment, etc. The aforementioned composition is effective in treating intraocular hypertension and glaucoma.
PURPOSE: Exploring the impact of contractures in adolescents and young adults (AYA) with spinal muscular atrophy (SMA) on daily functioning and participation and the impact of received contracture management.
METHODS: We included 14, non-ambulant AYA with SMA types 2/3 (10 females and 4 males), aged 16-30 years. Interviews focused on two topics: perceived impact of contractures on daily functioning and of previous contracture management. We used inductive thematic analysis for interview analysis.
RESULTS: In general, participants experienced muscle weakness to be more of a hindrance than contractures; they had adapted to their contractures over time. Participants considered contracture treatment useful when goals were meaningful and realistic. Participants mentioned that their perspective on contracture management would change in light of a promise of improved motor function due to disease-modifying treatment.
CONCLUSION: Despite the relatively low impact of contractures in comparison to the loss of muscle strength, non-ambulant AYA with SMA should be informed on the potential impact of contractures and benefits and potential adverse effects of their management. This information can support the shared decision-making process. While respecting individual choices, allows for incorporating interventions into daily life and the promotion of daily functioning and participation when children with SMA are growing up.
A method of inducing a generalized immune response, includes administering to a subject an immunologically effective amount of one or more isolated immunogenic peptides comprising an amino acid sequence set forth as SEQ. ID NO: 1-46, thereby inducing a generalized immune response to infection by a pathogen in a subject. A prophylactic or therapeutic composition for inducing a generalized immune response, includes an immunologically effective amount of one or more isolated immunogenic peptides comprising an amino acid sequence set forth as SEQ. ID NO: 1-46. A method of distinguishing a subject infected with a pathogen from a subject not so infected, includes detecting an antibody in the subject that selectively binds to one or more isolated immunogenic peptides comprising an amino acid sequence set forth as SEQ. ID NO: 1-46, wherein the presence of the antibody indicates that the subject is infected with the pathogen. A general method to discover broadly protective components for a vaccine is also disclosed.
Standard care: Those who opt to participate in the study will be randomly assigned to receive standard features of the media center (control group), or standard features plus the educational module intervention. They will complete online (1) a baseline patient activation survey (for patients old enough to complete and for caregivers) at the start of their participation, and (2) an end-of-study survey pre-discharge or at the end of the study period.
Start taking TAF at 24 weeks of gestation until delivery. The liver function, viral load and antigen status were reviewed monthly and 10 ml peripheral blood was collected.
Participants will receive challenge agent as two single oral doses of Indomethacin, one on Day -1 and one on Day 1. In addition, participants will receive lactulose-mannitol solution on Day -4 (baseline) and on Day 1 (post Indomethacin challenge).
OBJECTIVE: The aims of this study were to evaluate the adoption of and fidelity to the Coach2Move approach; identify differences between physical therapists with a specialization in geriatrics and physical therapists without a specialization; explore if level of adoption and specialization explain variances in effectiveness; and explore group differences in attitudes and experiences with implementation.
METHODS: A multi-methods process evaluation of Coach2Move implementation through 2 education days, 3 peer-assessment meetings, and an adapted electronic health record was performed alongside a cluster randomized stepped-wedge trial comparing regular care physical therapy with Coach2Move. Participants were 36 physical therapists with a specialization (n = 17) and without a specialization (n = 19) who treated 292 community-dwelling older adults. Level of adoption and fidelity were analyzed by comparing preimplementation scores with scores 1 year later. Coach2Move adoption was measured by e-assessment scores, and fidelity through health record indicators. The impact of specialization and adoption on health outcomes was examined using a mixed-model analysis of variance. Therapists' attitudes and experiences were collected through a survey based on semistructured interviews.
RESULTS: Mean (SD) total indicator scores on the e-assessment (adoption of a Coach2Move mindset) increased from baseline 17% (5%) to 47% (9%) at follow-up. Physical therapists with a specialization in geriatrics scored (mean [SD]) higher than physical therapists without (54% [6%] vs 41% [6%]). Mean (SD) indicator scores on health records (fidelity) increased from 35% (12%) at baseline to 47% (15%) at follow-up. Mean scores of physical therapists with a specialization in geriatrics were higher. Level of adoption and specialization (yes/no) did not explain the variance in effectiveness. Physical therapists identified important facilitators, including tailored education and peer-assessment meetings, whereas adequate reimbursement for the extra time investment was considered a necessity. Different workflows in practices were perceived as a barrier.
CONCLUSION: Implementation led to increased adoption and fidelity of the Coach2Move intervention by physical therapists but shows room for improvement. Attitudes toward the approach and its implementation were positive. Future implementation efforts on adoption could be improved by focusing on a fair compensation structure by third-party payers and insurance companies and optimizing organizational and financial context within practices.
IMPACT: This study evaluated the implementation of Coach2Move, a clinical reasoning approach designed to increase physical activity and improve self-efficacy in older adults. Overall, the study demonstrates the potential of Coach2Move to be effectively adopted by physical therapists. However, addressing therapist compensation and adapting to practice workflows are important considerations for successful large-scale implementation.
All patients referred to the Forzani MacPhail Colon Cancer Screening Centre (CCSC) in Calgary, Alberta, Canada for colonoscopy will be considered for inclusion. During pre-assessments at the clinic, patients are asked to consider a general research consent. If they agree to that, then they will be approached for consideration of participating in this study and presented with an "Invitation to Participate in a Research Study" form (appendix); the study assistant will obtain final consent if they agree. Those not interested in participating will simply receive their physician's standard bowel preparation protocol. There will be no coercion of any sort. Enrollment of participants will be performed with block randomizations of 8 by using a computer-generated table, with allocation concealment maintained through the use of consecutively numbered sealed envelopes. Colonoscopists and investigators will be blinded to allocation groups. Patients will be allocated to one of two groups: (1) oral Pico-Salax (two sachets, with 1.5-2L of water following each sachet) with Dulcolax (Bisacodyl, 4 tablets); (2) split dose Polyethylene Glycol-Based Lavage (2L + 2L).

A study assistant will assign patients to their group and instruct them on the proper use of their assigned bowel preparation method. Patients will be given a tolerability questionnaire, which has been modified from a previously used questionnaire, to be completed once their bowel preparation is finished and before coming to the CCSC for the colonoscopy (included in the appendix). Patient concerns or questions regarding the preparation will be directed toward the study assistant or clinic nurses as opposed to their endoscopist, so as to avoid un-blinding the Colonoscopist. The physician performing the procedure will then complete an Ottawa Bowel Preparation Scale and a validated Simplified Bowel Preparation scale to assess colon cleanliness.
BACKGROUND: Accidental hypothermia is common in all trauma patients and contributes to the lethal diamond, increasing both morbidity and mortality. In hypotensive shock, fluid resuscitation is recommended using fluids with a temperature of 37-42°, as fluid temperature can decrease the patient's body temperature. In Sweden, virtually all prehospital services use preheated fluids. The aim of the present study was to investigate how the temperature of preheated infusion fluids is affected by the ambient temperatures and flow rates relevant for prehospital emergency care.
METHODS: In this experimental simulation study, temperature changes in crystalloids preheated to 39 °C were evaluated. The fluid temperature changes were measured both in the infusion bag and at the patient end of the infusion system. Measurements were conducted in conditions relevant to prehospital emergency care, with ambient temperatures varying between - 4 and 28 °C and flow rates of 1000 ml/h and 6000 ml/h, through an uninsulated infusion set at a length of 175 cm.
RESULTS: The flow rate and ambient temperature affected the temperature in the infusion fluid both in the infusion bag and at the patient end of the system. A lower ambient temperature and lower flow rate were both associated with a greater temperature loss in the infusion fluid.
CONCLUSION: This study shows that both a high infusion rate and a high ambient temperature are needed if an infusion fluid preheated to 39 °C is to remain above 37 °C when it reaches the patient using a 175-cm-long uninsulated infusion set. It is apparent that the lower the ambient temperature, the higher the flow rate needs to be to limit temperature loss of the fluid.
Tirzepatide is available in single dose vials at six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg/0.5 mL. A study MC will administer the once-weekly SQ dose of tirzepatide. Consistent with tirzepatide's prescribing guidelines, participants will be initiated at a once-weekly SQ dose of 2.5 mg/week with a dose increase to 5mg/week at week 5. Consistent with tirzepatide's prescribing information, once the participant has received 5 mg/week for 4 weeks they are eligible for a dose increase if needed.
Parkinson's disease (PD) is a neurodegenerative disease characterized by dopaminergic neuron death and neuroinflammation. Emerging evidence points to the involvement of the transient receptor potential melastatin 2 (TRPM2) channel in neuron death and glial activation in several neurodegenerative diseases. However, the involvement of TRPM2 in PD and specifically its relation to the neuroinflammation aspect of the disease remains poorly understood. Here, we hypothesized that AG490, a TRPM2 inhibitor, can be used as a treatment in a mouse model of PD. Mice underwent stereotaxic surgery for 6-hydroxydopamine (6-OHDA) administration in the right striatum. Motor behavioral tests (apomorphine, cylinder, and rotarod) were performed on day 3 post-injection to confirm the PD model induction. AG490 was then daily injected i.p. between days 3 to 6 after surgery. On day 6, motor behavior was assessed again. Substantia nigra (SNc) and striatum (CPu) were collected for immunohistochemistry, immunoblotting, and RT-qPCR analysis on day 7. Our results revealed that AG490 post-treatment reduced motor behavior impairment and nigrostriatal neurodegeneration. In addition, the compound prevented TRPM2 upregulation and changes of the Akt/GSK-3β/caspase-3 signaling pathway. The TRPM2 inhibition also avoids the glial morphology changes observed in the PD group. Remarkably, the morphometrical analysis revealed that the ameboid-shaped microglia, found in 6-OHDA-injected animals, were no longer present in the AG490-treated group. These results indicate that AG490 treatment can reduce dopaminergic neuronal death and suppress neuroinflammation in a PD mouse model. Inhibition of TRPM2 by AG490 could then represent a potential therapeutical strategy to be evaluated for PD treatment.
BACKGROUND: High somatic comorbidity is common among patients in treatment for opioid use disorder (OUD). The present study aims to investigate changes in self-reported somatic health conditions and somatic symptoms among patients entering opioid maintenance treatment (OMT) programs.
METHODS: We used data from the Norwegian Cohort of Patients in OMT and Other Drug Treatment (NorComt) study. Of 283 patients who entered OMT, 176 were included for analysis at a 1-year follow-up. Participants provided self-reported data during structured interviews on somatic conditions, somatic symptoms, substance use severity measures, and mental distress. A multivariable linear regression analysis identified factors associated with changes in the burden of somatic symptoms.
RESULTS: Patients entering OMT reported a high prevalence of somatic conditions at the beginning of treatment, with 3 of 5 patients reporting at least one. The most prevalent condition was hepatitis C, followed by asthma and high blood pressure. Patients reported experiencing a high number of somatic symptoms. The intensity of these symptoms varied across a wide spectrum, with oral health complaints and reduced memory perceived as the most problematic. Overall, for the entire sample, there was no significant change in somatic symptoms from baseline to 1 year. Further analysis indicated that those who reported a higher burden of somatic symptoms at baseline had the greatest improvement at the 1-year follow-up. A higher number of somatic conditions and higher mental distress at baseline was associated with improvements in somatic symptoms burden at follow-up.
CONCLUSIONS: Patients in OMT report a range of somatic conditions and somatic symptoms. Given the wide range of symptoms reported by patients in OMT, including some at high intensity levels, healthcare providers should take into consideration the somatic healthcare needs of individuals in OMT populations.
CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov no. NCT05182918. Registered 10/01/2022 (the study was retrospectively registered).
ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.